Baltimore doctors sued for excessive stent surgeries; Ariosa inks Dx distribution deal;

 @FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev

 @MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce

 @DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce

> Ariosa Diagnostics has signed a deal to distribute Harmony, its prenatal test for trisomy 21, in the U.K. News (reg. req.)

> A number of doctors at St. Joseph Medical Center in metro Baltimore are being sued for performing heart stent procedures in hundreds of patients who didn't need them. Story

> BioInspire, an Illinois medical device startup incubator, has fostered 5 nascent device companies, and its efforts impressed former Mexican President Vicente Fox during his recent visit. Article

> LGTmedical is developing a platform that would allow vital-sign monitors to connect to smartphones through audio inputs. More

> Pennsylvania's CD Diagnostics, a developer of diagnostic tests for joint pain, has completed its purchase of Citrano Medical Laboratories. Release

> Gore has enrolled the first patients in a pivotal trial of its Gore Septal Occluder, designed to treat atrial septal defect. Release

> The Economic Times of India explores how med device and med-tech startups launched there are advancing onto the global stage. Story

Biotech News

 @FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech

 @JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce

> Novo's long-acting insulin degludec takes big step to megamarket status. Story

> Wanted: Premier hepatitis C drug developer to partner with Vertex. Article

> U.K.'s Redx blueprints big R&D spinoff funded by government grant. News

Pharma News

@FiercePharma: Generics makers need to change their spots--and learn marketing--to sell biosimilars, Actavis, CEO says. More | Follow @FiercePharma

> GSK CEO remains 'a huge bull on India.' Story

> EMA committee shoots down Vivus diet pill. Article

> Actavis CEO: Biosims market will be tough to crack. News

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.